MM-350: Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/s2152-2650(20)30956-3 ◽

2020 ◽

Vol 20 ◽

pp. S308-S309

Author(s):

Ajay K. Nooka ◽

Jonathan L. Kaufman ◽

Cesar Rodriguez ◽

Andrzej Jakubowiak ◽

Leyla Shune ◽

...

Keyword(s):

Multiple Myeloma ◽

African American ◽

Subgroup Analysis ◽

Newly Diagnosed ◽

Black Patients ◽

American Black

Download Full-text

Outcomes and prognostic factors in African American/black patients with mycosis fungoides and Sézary syndrome

European Journal of Cancer ◽

10.1016/s0959-8049(19)30534-9 ◽

2019 ◽

Vol 119 ◽

pp. S9

Author(s):

S. Geller ◽

E. Lebowitz ◽

M.P. Pulitzer ◽

S.M. Horwitz ◽

A.J. Moskowitz ◽

...

Keyword(s):

African American ◽

Prognostic Factors ◽

Mycosis Fungoides ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

Black Patients ◽

American Black

Download Full-text

Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.09.004 ◽

2019 ◽

Vol 19 (10) ◽

pp. e2-e3 ◽

Cited By ~ 1

Author(s):

Pieter Sonneveld ◽

Michel Attal ◽

Aurore Perrot ◽

Cyrille Hulin ◽

Denis Caillot ◽

...

Keyword(s):

Multiple Myeloma ◽

High Risk ◽

Subgroup Analysis ◽

Newly Diagnosed ◽

High Risk Patients ◽

Risk Patients

Download Full-text

Abstract 4913: Differences in presentation and survival outcomes for African American patients with newly diagnosed multiple myeloma

10.1158/1538-7445.am2019-4913 ◽

2019 ◽

Author(s):

Nisha Joseph ◽

Vikas A. Gupta ◽

Craig Hofmeister ◽

Charise Gleason ◽

Leonard T. Heffner ◽

...

Keyword(s):

Multiple Myeloma ◽

African American ◽

Survival Outcomes ◽

Newly Diagnosed

Download Full-text

PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

HemaSphere ◽

10.1097/01.hs9.0000567032.31064.27 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 962

Author(s):

A. Belch ◽

N. Bahlis ◽

D. White ◽

M. Cheung ◽

C. Chen ◽

...

Keyword(s):

United States ◽

Multiple Myeloma ◽

Subgroup Analysis ◽

The United States ◽

Newly Diagnosed ◽

Phase 3

Download Full-text

Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study—Asian Subgroup Analysis

Advances in Therapy ◽

10.1007/s12325-020-01395-x ◽

2020 ◽

Vol 37 (7) ◽

pp. 3404-3416

Author(s):

Shang-Yi Huang ◽

Sung-Soo Yoon ◽

Kazuyuki Shimizu ◽

Wee Joo Chng ◽

Cheng-Shyong Chang ◽

...

Keyword(s):

Multiple Myeloma ◽

Zoledronic Acid ◽

Bone Disease ◽

Subgroup Analysis ◽

Newly Diagnosed ◽

Disease Treatment ◽

Phase 3 ◽

Double Blind ◽

Randomized Controlled

Download Full-text

Abstract 4913: Differences in presentation and survival outcomes for African American patients with newly diagnosed multiple myeloma

10.1158/1538-7445.sabcs18-4913 ◽

2019 ◽

Author(s):

Nisha Joseph ◽

Vikas A. Gupta ◽

Craig Hofmeister ◽

Charise Gleason ◽

Leonard T. Heffner ◽

...

Keyword(s):

Multiple Myeloma ◽

African American ◽

Survival Outcomes ◽

Newly Diagnosed

Download Full-text

Roles of Perceived Provider Cultural Sensitivity and Health Care Justice in African American/Black Patients’ Satisfaction with Provider

Journal of Clinical Psychology in Medical Settings ◽

10.1007/s10880-014-9397-0 ◽

2014 ◽

Vol 21 (3) ◽

pp. 282-290 ◽

Cited By ~ 10

Author(s):

Carolyn M. Tucker ◽

Bonnie Moradi ◽

Whitney Wall ◽

Khanh Nghiem

Keyword(s):

Health Care ◽

African American ◽

Cultural Sensitivity ◽

Patients Satisfaction ◽

Black Patients ◽

American Black ◽

Health Care Justice

Download Full-text

Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

Haematologica ◽

10.3324/haematol.2013.087585 ◽

2013 ◽

Vol 99 (1) ◽

pp. 148-154 ◽

Cited By ~ 70

Author(s):

C. Scheid ◽

P. Sonneveld ◽

I. G. H. Schmidt-Wolf ◽

B. van der Holt ◽

L. e. Jarari ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Renal Impairment ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Subgroup Analysis ◽

Prognostic Impact ◽

Newly Diagnosed ◽

Before And After

Download Full-text

Phase 3 FIRST Trial in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Patients From Canada and the United States

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.09.374 ◽

2019 ◽

Vol 19 (10) ◽

pp. e225

Author(s):

Andrew Belch ◽

Nizar J. Bahlis ◽

Darrell White ◽

Matthew Cheung ◽

Christine Chen ◽

...

Keyword(s):

United States ◽

Multiple Myeloma ◽

Subgroup Analysis ◽

The United States ◽

Newly Diagnosed ◽

Phase 3

Download Full-text

Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2021.06.005 ◽

2021 ◽

Author(s):

Maria-Victoria Mateos ◽

Meletios A. Dimopoulos ◽

Michele Cavo ◽

Kenshi Suzuki ◽

Stefan Knop ◽

...

Keyword(s):

Multiple Myeloma ◽

Subgroup Analysis ◽

Newly Diagnosed

Download Full-text